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ABSTRACT 
 
 
 
Background: Clinical breakpoints and epidemiological cut-off values for N. gonorrhoeae azithromycin 
antimicrobial susceptibility testing have not been established. This study utilized existing minimum 
inhibitory concentration (MIC) data from CDC’s Gonococcal Isolate Surveillance Project (GISP) to 
establish epidemiological cut-off values for azithromycin and N. gonorrhoeae as determined by agar 
dilution. 
 
Methods: MIC distributions for the pooled dataset and each data year (2005-2012) were constructed. 
Epidemiological cut-off values were calculated using two methods. Method 1 considers the wild-type 
MIC distribution, the modal MIC for the distribution, and the inherent variability of the test (±1 twofold-
dilution). Method 2 defines the epidemiological cut-off value as two twofold-dilutions higher than the 
MIC50. 
 
Results: Taking into consideration the wild-type MIC distributions and the inherent variability of the 
test, the epidemiological cut-off value chosen for the pooled dataset and each data year using Method 1 
was ≤1.0 µg/mL. The MIC50 for the pooled dataset and each data year was 0.25 µg/mL. Two twofold-
dilutions higher than the MIC50 (0.25 µg/mL) for the pooled dataset and each data year was 1.0 µg/mL.                        
 
Discussion: The epidemiological cut-off values chosen using methods 1 and 2 (≤1.0 µg/mL) were 
identical for the pooled dataset and each data year, indicating the epidemiological cut-off value has not 
changed from 2005-2012. The epidemiological cut-off value for N. gonorrhoeae azithromycin agar 
dilution antimicrobial susceptibility testing established during this study can be used to help set clinical 
breakpoints and identify isolates with reduced susceptibility to azithromycin. 
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CHAPTER I 
INTRODUCTION 
 
Gonorrhea is the second most commonly reported notifiable disease in the United States.  
It is estimated that there are over 820,000 new gonorrhea infections annually. Untreated 
gonorrhea infections can cause serious and permanent health conditions in both men and women. 
Gonorrhea can be treated with appropriate antimicrobial therapy, but increasing resistance to 
commonly prescribed drugs may complicate our ability to treat infections in the near future.  
Because Neisseria gonorrhoeae has developed resistance to many antibiotic therapies 
used to treat gonococcal infections (penicillin, fluoroquinolones, oral cephalosporins), 
antimicrobial susceptibility testing is becoming increasingly important to monitor resistance 
trends and guide treatment. National, state, and private laboratories performing antimicrobial 
susceptibility testing utilize the clinical breakpoints, or interpretive criteria, established by the 
Clinical and Laboratory Standards Institute (CLSI) to differentiate between susceptible, 
intermediate, and resistant bacterial isolates. Unfortunately, clinical breakpoints have not been 
established for any N. gonorrheae azithromycin antimicrobial susceptibility testing method. 
CDC currently recommends azithromycin, along with single-dose injectable cephalosporin 
regimens, to treat uncomplicated gonococcal infections of the cervix, urethra, and rectum. As 
such, interpretive criteria for N. gonorrhoeae azithromycin antimicrobial susceptibility testing 
are needed to monitor resistance and guide treatment regimens. 
CLSI’s methodology for establishing clinical breakpoints requires microbiological, 
pharmokinetic, and clinical data. In the absence of established clinical breakpoints, 
epidemiological cut-off values can be used to identify isolates without resistance mechanisms 
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(wild type) from non-wild type isolates. This study will utilize existing Minimum Inhibitory 
Concentration (MIC) data from CDC’s Gonococcal Isolate Surveillance Project (GISP) to 
establish epidemiological cut-off values for azithromycin and N. gonorrhoeae as determined by 
agar dilution. 
 
Research Questions 
1. Do the MIC distributions for N. gonorrhoeae azithromycin agar dilution 
antimicrobial susceptibility testing differ from 2005-2012? 
2. What is the epidemiological cut-off value for azithromycin for 2005-2012? Does 
the epidemiological cut-off value differ from 2005-2012? 
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CHAPTER II 
REVIEW OF THE LITERATURE 
 
2.1 Neisseria gonorrhoeae and Gonococcal Infection 
Neisseria gonorrhoeae (gonococci) is the bacterium that causes gonorrhea and its associated 
clinical syndromes. Gonorrhea is transmitted through vaginal, oral, or anal sex and can also be 
transmitted from a mother to her unborn baby during childbirth. The World Health Organization 
(WHO) estimated there were 106.1 million new cases of gonorrhea infections worldwide in 
adults in 2008 (1). Gonorrhea is the second most commonly reported notifiable infection in the 
United States. There were 321,849 cases reported in 2011 yielding a 4% increase in incidence 
from 2010. Rates are highest in the Southern region of the United States, among women, and 
persons 20-24 years of age (2).  
The broad spectrum of clinical manifestations includes symptomatic and asymptomatic local 
infection, complicated local infection, and systemic infection. While the majority of 
uncomplicated gonococcal infections are asymptomatic, the most common presentation of 
gonococcal infection in men is acute anterior urethritis accompanied by urethral discharge and/or 
dysuria (painful urination). Untreated gonococcal infections typically resolve over a period of 
several weeks and most patients become asymptomatic within six months. Complications, while 
rare in developed countries, include epididymitis, lymphangitis, penile edema, acute or chronic 
prostatitis, and periurethral abscesses (3).   
The most common infection site in women is the endocervical canal, but urethral 
colonization followed by infection of the periurethral (Skene’s) gland or Bartholin’s gland ducts 
are also common in the absence of endocervical infection. Symptoms may include increased 
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vaginal discharge, dysuria, intermenstrual uterine bleeding, and heavy or prolonged menstrual 
periods (menorrhagia) (4). Pelvic inflammatory disease (PID), or the infection and inflammation 
of the upper genital tract, is the most common complication of gonorrhea in women. PID is 
accompanied by endometritis, tubo-ovarian abscess, or pelvic peritonitis and is also the most 
important complication in terms of public health impact due to its associated long term sequelae 
which include infertility, ectopic pregnancy, and chronic pelvic pain. It is estimated that between 
10-20% of women with gonorrhea develop PID, and approximately eight percent of women in 
the United States develop PID in their lifetime. Prevalence is much higher in developing 
countries with rates as high as 32% (5-6). 
 Rectal infection is common in men who have sex with men (MSM), and up to 60% of 
women with gonococcal cervicitis also have infection of the rectal mucosa. While infection of 
the rectum in women is normally asymptomatic, rectal infection in men can be associated with 
overt proctitis (7). Isolated pharyngeal infection has been documented in 3-7% of heterosexual 
men, 10-20% of heterosexual women, and 10-25% of men who have sex with men. The majority 
of infections are asymptomatic, but association with acute pharyngitis, tonsillitis, fever, or 
cervical lymphadenopathy has been reported (4).  
Gonococcal conjunctivitis and primary cutaneous gonorrhea, characterized by localized 
ulcers of the genitals and skin lesions, are rare (4). Disseminated (or systemic) gonococcal 
infection (DGI) is also rare and occurs in 0.2-1.9% of cases. DGI can occur in both males and 
females, but incidence is thought to be higher in females. Symptoms include fever, joint pain, 
skin rashes, and tenosynovitis. In very rare cases, disseminated gonococcal infection may 
progress to endocarditis (8).  
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N. gonorrhoeae and Chlamydia trachomatis co-infection is common. One cross sectional 
study of new clients presenting to a hospital-based STD clinic in the United Kingdom found that 
39% of 1,239 women and 24% of 1,141 heterosexual men with gonorrhea also had chlamydia. In 
addition, more than half of the women and a third of the men 15-19 years of age were co-
infected (9). Similarly, a study of adolescents entering selected United States detention centers 
found that 54% of females and 51% of males with gonorrhea were also infected with chlamydia 
(10). It is also widely understood that sexually transmitted infections (STIs) such as gonorrhea 
increase the risk of acquiring and transmitting human immunodeficiency virus (HIV) by two to 
five-fold and that aggressive STI prevention, screening, and treatment reduces the transmission 
of HIV (11). 
There are several populations that have a higher risk of acquiring STIs or experiencing 
adverse health outcomes as a result of acquiring an STI. It is estimated that young people 15-24 
years of age account for more than half of new STI cases in the United States. Risk factors such 
as engagement in high-risk sexual behaviors and barriers to accessing quality STI prevention 
services and care (concerns about confidentiality, lack of health insurance or ability to pay) 
increases adolescents’ and young adults’ risk of acquiring gonorrhea (2). MSM represent an 
estimated 2% of the United States male population, but they account for 59% of the people living 
with HIV in the country. Because the risk factors that contribute to the transmission of STIs 
(higher number of lifetime sex partners, higher partner acquisition rates, unprotected sex) also 
increase the acquisition and transmission of HIV, MSM also bear a disproportionately high 
burden of STIs (12, 13). 
Gonorrhea affects approximately 13,200 pregnant women annually (14). Untreated infections 
can lead to adverse pregnancy outcomes such as early onset of labor, spontaneous preterm birth, 
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low birth weight, preterm rupture of membranes surrounding the uterus, miscarriage, and 
stillbirth (15-17). Gonorrhea can also be transmitted from an infected mother to her baby during 
delivery. Gonococcal ophthalmia neonatorum is the most common presentation of gonorrhea in 
neonates, but scalp abscesses, wound infections, systemic disease (meningitis and sepsis), and 
colonization of the oropharynx and gastric fluid can also occur (18). Genital infection in children 
is rare and typically acquired through sexual abuse (19). 
 
2.2 History of Treatment and Antibiotic Resistance Trends 
Silver proteinate or Protargol was used to treat gonorrhea from the late 1890’s up to the 
introduction of antibiotics in the mid 1930’s. The sulfonamides were the first effective 
antimicrobials against gonorrhea, but resistance was widespread by the mid-1940’s. Penicillin 
became the first line drug for treatment in 1943. Within 10-15 years treatment failures had been 
reported, and higher doses were required for successful treatment. By 1989 penicillin was no 
longer recommended for the treatment of gonorrhea. Streptomycin and chloramphenicol 
(introduced in 1949), erythromycin (introduced in 1952), spectinomycin (introduced in 1961), 
and tetracycline (introduced in 1962) were used when treatment with penicillin was 
contraindicated, but strains resistant to these antibiotics emerged rapidly due to chromosomal 
mutations and other gene acquisition events. By the late 1980’s most of these alternatives were 
no longer recommended for treatment (20). 
Fortunately third generation cephalosporins such as ceftriaxone and cefixime and 
fluoroquinolones such as ciprofloxacin were highly effective against gonococci. By 1985 
ceftriaxone became the recommended treatment for uncomplicated gonococcal infections, and in 
1993, the oral fluoroquinolones (ciprofloxacin and ofloxacin) and cefixime were the 
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recommended first line treatment (21). Resistance to fluorquinolones was recorded as early as 
the mid-1990’s in South East Asia and in the United States as early as 1991 (Hawaii). Increasing 
resistance to fluoroquinolones in the United States prompted the CDC to recommend the use of 
cephalosporins over fluorquinoloes in Hawaii and California in 2002. This recommendation was 
later expanded to include MSM in 2004, and fluoroquinolones were no longer recommended in 
the United States by 2007 (22).  
In recent years decreased susceptibility to third generation cephalosporins has been reported 
from Asia and the Pacific region as well as Europe, Canada, and the United States. Cefixime 
treatment failures were first reported in Japan in 2003 and have subsequently been reported in 
the United Kingdom, Norway, Austria, and France. Widespread resistance to oral cephalosporins 
prompted Japan to discontinue the use of cefixime for the treatment of gonorrhea in 2006.  
In 2009, a strain with high-level ceftriaxone resistance was isolated in Kyoto, Japan from a 
woman presenting with pharyngeal gonococcal infection. Subsequently, isolates with high-level 
resistance to ceftriaxone have been identified in men with urogenital infections in Spain and 
France (23). While ceftriaxone treatment failures have not yet been documented in the United 
States, data from CDC’s GISP suggest the number of isolates with elevated ceftriaxone MIC’s 
has markedly increased since 2006, particularly in the western region and among MSM (24). 
CDC’s current treatment guidelines recommend combination therapy with 250 mg ceftriaxone 
intramuscularly and either 1 g azithromycin orally as a single treatment or 100 mg doxycycline 
twice daily for seven days (25). 
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2.3 Azithromycin and the Treatment of Gonorrhea 
Azithromycin is an azalide drug derived from the macrolide class of antibiotics. The 
mechanism of action is inhibition of RNA-dependent peptide synthesis of bacteria by binding to 
the 50s ribosomal subunit. Azithromycin became available for the treatment of gonorrhea in 
1983, and it has proven effective as a single dose alternative to oral cephalosporins in 
combination with ceftriaxone. It has also proven highly effective against pharyngeal infection, 
genital co-infection with C. trachomatis, and penicillin-resistant strains (26). Azithromycin, in 
combination with ceftriaxone, is one of the currently recommended first-line treatment regimens 
for uncomplicated gonococcal infections in the United States.  
Resistance to azithromycin was first reported in the United States in New Mexico in 1993. 
The first isolate demonstrating high level resistance in the United States was identified in Hawaii 
in 2011 (27); however, data from GISP suggests the proportion of isolates with high level 
resistance to azithromycin remains low (28). 
 
2.4 The Gonococcal Isolate Surveillance Project (GISP) 
CDC established a national sentinel surveillance system known as the Gonococcal Isolate 
Surveillance Project (GISP) in 1986 to 1) to monitor trends in antimicrobial resistance in N. 
gonorrhoeae strains, 2) to characterize male patients with gonorrhea, especially those infected 
with strains that are resistant to currently recommended therapies, and 3) to describe the diversity 
of antimicrobial resistance in N. gonorrhoeae by phenotypically characterizing resistant isolates 
via the agar dilution method. This method provides an MIC (vs. zone diameter), is well-
characterized, and well-standardized, and as such, is considered the gold standard for N. 
gonorrhoeae antimicrobial susceptibility testing. CDC prepares and distributes an annual report 
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of the project’s findings, and data generated by GISP is used to inform selection of therapies for 
gonococcal infection and to revise CDC’s STD Treatment Guidelines (29). 
 
2.5 Clinical Breakpoints and Epidemiological Cut-off Values 
Clinical breakpoints (CBPs) are values used by laboratories to classify MIC or zone 
inhibition data generated from antimicrobial susceptibility assays into clinically relevant 
categories i.e., susceptible, intermediate, or resistant to a particular antimicrobial agent (30). 
Clinical breakpoints influence local, regional, and national treatment guidelines by categorizing 
the susceptibility of previously tested isolates for a particular antimicrobial. In addition, clinical 
breakpoints guide empiric treatment (31).  
The Clinical and Laboratory Standards Institute (formerly known as the National Committee 
for Clinical Laboratory Standards), established in 1968, is the international organization 
responsible for developing the clinical laboratory testing standards used in the United States. 
CLSI laboratory standards are established utilizing input from and consensus among 
government, industry, and healthcare professionals. CLSI’s methodology for establishing clinical 
breakpoints requires four main data types: (i) MIC (minimum inhibitory concentration) 
distributions and epidemiological cut-off values (ECVs); (ii) phenotypic and genotypic in vitro 
resistance markers; (iii) pharmokinetic data from animal models and human studies; and (iv) 
clinical and bacteriological outcome data from clinical studies (32).  
Currently there are no CLSI-established azithromycin clinical breakpoints for any N. 
gonorrhoeae antimicrobial susceptibility testing method. In the absence of established clinical 
breakpoints, epidemiological cut-off values can serve as a guide to differentiate wild-type strains 
from strains with acquired resistance mechanisms. The construction of MIC distributions and the 
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determination of epidemiological cut-off values is the first step in the development of clinical 
breakpoints for azithromycin agar dilution antimicrobial susceptibility testing for N. 
gonorrhoeae.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
CHAPTER III 
 
METHODS 
 
 
 
3.1 Definitions 
 
MIC, or minimum inhibitory concentration, is defined as the lowest concentration of 
antibiotic needed to inhibit visible growth of a microorganism in a laboratory. Wild-type, in the 
context of this study, is defined as lacking acquired or mutational antibiotic resistance 
mechanisms. ECV, or epidemiological cut-off value (synonymous with wild-type cut-off value), 
is defined as the MIC value which best describes the end of the wild-type distribution. It is 
expressed as ECV ≤ X µg/mL (33). Pooled dataset refers to data from 2005-2012. Raw MIC 
data refers to untransformed MIC values. MIC50 is defined as the value at which 50% of the 
isolates are inhibited. MIC99 is defined as the value at which 99% of the isolates are inhibited. 
 
3.2 GISP Specimen Collection and Agar Dilution Susceptibility Testing 
GISP sentinel STD clinics and regional laboratories are chosen for a 5-year term via an 
application process administered by a CDC Funding Opportunity Announcement (FOA). STD 
clinics and laboratories chosen as GISP sentinel sites and regional laboratories receive funding 
from CDC to assist with GISP program requirements. Each month around 24 sentinel STD 
clinics submit urethral isolates from the first 25-30 male patients presenting with urethral 
gonococcal infection as well as clinical and demographic data to one of five regional 
laboratories. The five current regional laboratories, located in Atlanta, Austin, Birmingham, 
Cleveland, and Seattle, test the isolates for β-lactamase production via the Nitrocefin test and 
antimicrobial susceptibility (minimum inhibitory concentrations, MIC’s) to  penicillin G, 
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tetracycline, spectinomycin, cefixime, ceftriaxone, ciprofloxacin, and azithromycin via the agar 
dilution method. Results are reported to CDC on a monthly basis, and any isolate meeting Alert 
Value MIC criteria (currently ≥ 2.0 µg/mL for azithromycin) undergoes confirmatory retesting 
by the regional laboratory (34). 
 
3.3 GISP Azithromycin MIC Data 
Azithromycin was added to the GISP panel in 1992, and azithromycin MIC data is 
available from 1992-2012. In 2005 there was a change in media used for agar dilution testing 
among all GISP regional laboratories. This media change resulted in an observational shift of the 
MIC distribution approximately equal to one twofold-dilution higher (35). Data from 1992-2004 
were excluded from this analysis to ensure the consistency of laboratory methods for data 
collection.  
 
3.4 MIC Distributions 
MIC distributions for azithromycin were constructed for 2005-2012 using Microsoft 
Excel v.2010. 
 
3.5 Statistical Analysis 
All statistical analyses were performed using SAS/STAT® v.9.3 software (SAS Institute, 
Cary, North Carolina, USA). The univariate procedure was used to fit pooled azithromycin MIC 
values to normal and lognormal curves to test for normality. Data were then log2 transformed as 
described previously, and the univariate procedure was again used to fit log2-transformed MIC 
values to normal and lognormal curves to test for normality. Levene’s test (glm procedure) and 
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one-way analysis of variance (ANOVA) were used with raw MIC data to test for homogeneity of 
variances and differences in mean azithromycin MIC from 2005-2012 (36). The Kruskal- Wallis 
test was conducted on raw MIC data using the npar1way procedure to test for underlying 
differences in the azithromycin MIC distributions from 2005-2012 (α = 0.05). The Wilcoxon-
Mann-Whitney test was then used to test for differences in the azithromycin MIC distribution 
from year to year (i.e., 2005-2006, 2006-2007, etc.) using raw MIC data (α = 0.05). The 
univariate procedure was then used to calculate the median, mode, MIC50, MIC90, and MIC99 for 
each data year and the pooled dataset. 
 
3.6 Calculation of Epidemiological Cut-off Values 
 Two methods were used to calculate epidemiological cut-off values. Method 1, often 
called the “eyeball method,” considers the wild-type MIC distribution, the modal MIC for the 
distribution, and the inherent variability of the test (±1 twofold-dilution) to determine the 
epidemiological cut-off value. In addition, the epidemiological cut-off value should encompass 
at least 95% of the isolates in the wild-type distribution (37). The mode and modal MIC ±1 
twofold-dilution were calculated for each data year. MIC values that 1) were larger than the 
modal MIC +1 twofold-dilution and 2) included at least 95% of isolates in the wild-type 
distribution were used to identify epidemiological cut-off values via visual inspection of each 
MIC distribution. Method 2 defines the epidemiological cut-off value as two twofold-dilutions 
higher than the MIC50 (38).  
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CHAPTER IV 
 
RESULTS 
 
 
 
4.1 MIC Distributions and Descriptive Statistics 
 
Azithromycin MIC distributions for data years 2005-2006 can be found below in Figures 
1-8. 
 
 
Figure 1. MIC distribution for azithromycin, 2005. 
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Figure 2. MIC distribution for azithromycin, 2006. 
 
 
 
Figure 3. MIC distribution for azithromycin, 2007. 
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Figure 4. MIC distribution for azithromycin, 2008. 
 
 
 
Figure 5. MIC distribution for azithromycin, 2009. 
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Figure 6. MIC distribution for azithromycin, 2010. 
 
 
 
Figure 7. MIC distribution for azithromycin, 2011. 
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Figure 8. MIC distribution for azithromycin, 2012. 
 
 
 
 
There were 6,199 observations in 2005,  6,089 observations in 2006,  6,009 observations 
in 2007,  5,723 observations in 2008,  5,630 observations in 2009,  5,693 observations in 2010,  
5,467 observations in 2011,  and 5,495 observations in 2012 for a total of 46,305 observations 
from 2005-2012. The mean MIC values for each data year, 2005-2012, were 0.281 µg/mL, 0.283 
µg/mL, 0.343 µg/mL, 0.337 µg/mL, 0.290 µg/mL, 0.303 µg/mL, 0.264 µg/mL , and 0.311 
µg/mL, respectively. The mean MIC value for the pooled dataset was 0.301 µg/mL. The median 
azithromycin MIC (or MIC50) for each data year and the pooled dataset was 0.250 µg/mL. 
Descriptive statistics are summarized in Table 1. 
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Table 1. Descriptive statistics, GISP azithromycin MIC data, 2005-
2012. 
 
 N 
Mean 
(µg/mL) 
Median 
(µg/mL) 
Mode 
(µg/mL) 
Range 
(µg/mL) 
2005 6,199 0.281 0.250 0.250 15.99 
2006 6,089 0.283 0.250 0.250 15.99 
2007 6,009 0.343 0.250 0.250 15.99 
2008 5,723 0.337 0.250 0.250 15.97 
2009 5,630 0.290 0.250 0.250 15.99 
2010 5,693 0.303 0.250 0.250 15.99 
2011 5,467 0.265 0.250 0.250 15.99 
2012 5,495 0.311 0.250 0.250 255.99 
2005-
2012 
46,305 0.301 0.250 0.250 255.99 
 
 
4.2 Goodness-of-fit Tests for Normality and Equal Variances 
 
 There is statistically significant evidence that the pooled dataset is not normally 
distributed. The azithromycin MIC distribution for 2005-2012 (pooled dataset) fit poorly to 
normal and lognormal distributions as indicated by the Anderson-Darling goodness-of-fit tests 
(Table 2). The p values for both normal and lognormal distributions were <0.005 (α = 0.05). 
Log2 transformation of MIC values did not improve fit for either distribution. Levene’s test for 
homogeneity of variance indicated equal variances among the eight data years (2005-2012) with 
an F statistic of 1.06 and a p value of 0.3883 (α =0.05).  
 
 
Table 2. Anderson-Darling goodness-of-fit tests, GISP azithromycin MIC data, 2005-2012. 
 A
2
 p (α =0.05) 
Normal  Distribution 12361.38 <0.005 
Lognormal Distribution 1515.70 <0.005 
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4.3 Tests for Differences in Azithromycin MIC Distributions 
 
 ANOVA indicated the mean azithromycin MIC differed significantly among the data 
years, 2005-2012 (F statistic = 2.62 and p = 0.0104; α = 0.05). While the median MIC for the 
pooled dataset and each data year were equivalent at 0.25 µg/mL, the Kruskal-Wallis test also 
indicated a statistically significant difference in the underlying azithromycin MIC distributions 
for the pooled dataset (χ2 = 849.87; p = <0.0001). There were no statistically significant 
differences in the azithromycin MIC distributions from 2007-2008 (Z = 0.44; p =0.6585), 2010-
2011 (Z = -1.50; p = 0.1330), and 2011-2012 (Z = -1.89; p = 0.0593). Table 3 shows the results 
of the Wilcoxon-Mann-Whitney two-sample comparisons. 
 
 
Table 3. Comparison of azithromycin MIC distributions using the Wilcoxon-Mann-
Whitney two-sample test, 2005-2012. 
 Z p (α =0.05) 
2005-2006 6.35 <0.0001 
2006-2007 10.91 <0.0001 
2007-2008 0.44
*
 0.6585
*
 
2008-2009 -13.26 <0.0001 
2009-2010 3.55 0.0004 
2010-2011 -1.50
* 
0.1330
*
 
2011-2012 -1.89
* 
0.0593
*
 
*No statistically significant difference in azithromycin MIC distributions. 
 
 
 
4.4 Epidemiological Cut-off Values (ECVs)  
As referenced in Table 1, the modal MIC for the pooled dataset and each azithromycin 
MIC distribution (2005-2012) was 0.25 µg/mL. The modal MIC ±1 twofold-dilution for the 
pooled dataset and each data year ranged from 0.125 to 0.5 µg/mL. Taking into consideration the 
wild-type MIC distributions (Figures 1-8) and the inherent variability of the test, the 
epidemiological cut-off value chosen for the pooled dataset and each data year using Method 1 
21 
 
was ≤1.0 µg/mL (Table 4). This cut-off encompassed 99% of the MICs in the pooled dataset and 
each data year. 
The MIC50 for the pooled dataset and each data year was 0.25 µg/mL. Two twofold-
dilutions higher than the MIC50 (0.25 µg/mL) for the pooled dataset and each data year was 1.0 
µg/mL. The epidemiological cut-off value chosen for the pooled dataset and each data year using 
Method 2 was ≤1.0 µg/mL (Table 4). Again, the chosen epidemiological cut-off value 
encompassed 99% of MICs in the pooled dataset and each data year. 
The epidemiological cut-off values were identical for Methods 1 and 2 for each data year 
and the pooled dataset (Figure 9). 
 
 
 
 
Table 4. ECVs obtained from GISP Azithromycin MIC† data, 2005-2012 
Year N Mode MIC50 MIC99 
Method 1 
ECV* 
Method 2 
ECV** 
2005 6,199 0.25 0.25 1.0 1.0 1.0 
2006 6,089 0.25 0.25 1.0 1.0 1.0 
2007 6,009 0.25 0.25 1.0 1.0 1.0 
2008 5,723 0.25 0.25 1.0 1.0 1.0 
2009 5,630 0.25 0.25 1.0 1.0 1.0 
2010 5,693 0.25 0.25 1.0 1.0 1.0 
2011 5,467 0.25 0.25 1.0 1.0 1.0 
2012 5,495 0.25 0.25 1.0 1.0 1.0 
2005-2012 46,305 0.25 0.25 1.0 1.0 1.0 
 
†MIC (µg/mL) 
*ECV considers the wild-type MIC distribution, the modal MIC, the inherent variability of the test (±1 twofold 
dilution), and should encompass at least 95% of isolates in the wild-type distribution. 
**ECV = two twofold dilution steps higher than MIC50 
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Figure 9. Epidemiological cut-off value for azithromycin, 2005-2012. 
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CHAPTER V 
 
DISCUSSION 
 
 
 
5.1 Implications  
 
 This study aimed to 1) determine if azithromycin MIC distributions for N. gonorrhoeae 
have changed from 2005-2012 and 2) to calculate epidemiological cut-off values for 2005-2012 
GISP azithromycin agar dilution MIC data and determine whether or not the epidemiological 
cut-off values differ during this time period. A statistically significant difference in the 
underlying MIC distributions was observed between the eight data years; however, no 
statistically significant differences were found in MIC distributions from 2007-2008, 2010-2011, 
and 2011-2012. Interestingly, while the Wilcoxon-Mann-Whitney test demonstrated statistically 
significant differences in the MIC distributions from 2005-2006, 2006-2007, 2008-2009, and 
2009-2010, the median azithromycin MIC for the pooled data set and each data year were 
identical at 0.25µg/mL. This is most likely due to the large sample sizes as the difference in 
ranks were large enough to be significant despite equal medians. 
The epidemiological cut-off value selected for each data year and the pooled dataset was 
≤1.0 µg/mL indicating the epidemiological cut-off value did not change from 2005-2012. While 
the Kruskal-Wallis test indicated a statistically significant difference in the underlying MIC 
distributions from 2005-2012, the lack of change in epidemiological cut-off value indicates the 
wild-type distribution has not shifted during this time period. In addition, the epidemiological 
cut-off values chosen using Method 1 and Method 2 were identical, suggesting that, for this 
dataset, both methods were comparable. Using this epidemiological cut-off value, isolates with 
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an MIC less than or equal to 1.0 µg/mL may be considered wild-type, whereas isolates with an 
MIC of  2.0 µg/mL or higher may have decreased susceptibility to azithromycin.  
 
5.2 Future Considerations 
 More robust statistical procedures for the calculation of epidemiological cut-off values 
have been described previously for different bacteria-antimicrobial combinations, but 
comparison studies of these methods to Methods 1 and 2 used in this study show comparable 
results, usually within one twofold-dilution (39-42). As a result, only methods 1 and 2 were used 
for this analysis. Application of these statistical methods may be useful in the future for the 
establishment of clinical breakpoints for azithromycin agar dilution antimicrobial susceptibility 
testing for N. gonorrhoeae. In addition, genotypic markers of resistance were not included in this 
study. Examination of MIC distributions in tandem with molecular markers of resistance can 
provide a better understanding of the clinical importance of isolates with reduced susceptibility 
to azithromycin by confirming if such isolates harbor resistance mechanisms. Lastly, agar 
dilution antimicrobial susceptibility testing capacity for N. gonorrhoeae is limited in the United 
States. Similar studies should be conducted utilizing zone diameter and MIC data collected via 
E-tests to establish epidemiological cut-off values for azithromycin disk diffusion and E-test 
procedures. 
One gram azithromycin given orally in combination with 250mg ceftriaxone given as a 
single intramuscular dose is one of two currently recommend treatment regimens for 
uncomplicated gonococcal infections of the cervix, urethra, and rectum. As such, clinicians 
require azithromycin antimicrobial susceptibility data to monitor resistance. Clinical laboratories 
may be reluctant to perform azithromycin antimicrobial susceptibility testing for N. gonorrhoeae 
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because results are difficult to interpret without established clinical breakpoints. The lack of 
established breakpoints for N. gonorrhoeae azithromycin antimicrobial susceptibility testing 
hinders surveillance and hampers the management of patients who fail treatment. While 
epidemiological cut-off values cannot replace clinical breakpoints, they are the first crucial step 
in the establishment of clinical breakpoints by CLSI and other standard-setting institutes. The 
epidemiological cut-off value for azithromycin and N. gonorrhoeae agar dilution antimicrobial 
susceptibility testing established here can be used to help set clinical breakpoints and identify 
isolates with reduced susceptibility to azithromycin.  
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